{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:16:12Z","timestamp":1789578972526,"version":"build-2803163510"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40618-020-01269-7","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T16:02:16Z","timestamp":1587830536000},"page":"1409-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Biochemical bone turnover markers in hormonal disorders in adults: a narrative review"],"prefix":"10.1007","volume":"43","author":[{"given":"P.","family":"Szulc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"1269_CR1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1530\/acta.0.0970018","volume":"97","author":"J Halse","year":"1981","unstructured":"Halse J, Melsen F, Mosekilde L (1981) Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol (Copenh) 97:18\u201322","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1269_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11102-017-0847-1","volume":"21","author":"L Dalle Carbonare","year":"2018","unstructured":"Dalle Carbonare L, Micheletti V, Cosaro E et al (2018) Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 21:56\u201364. https:\/\/doi.org\/10.1007\/s11102-017-0847-1","journal-title":"Pituitary"},{"key":"1269_CR3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.EJ13-0387","volume":"61","author":"D Tamada","year":"2014","unstructured":"Tamada D, Kitamura T, Onodera T et al (2014) Rapid decline in bone turnover markers but not bone mineral density in acromegalic patients after transsphenoidal surgery. Endocr J 61:231\u2013237","journal-title":"Endocr J"},{"key":"1269_CR4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/eje.1.02285","volume":"155","author":"T Ueland","year":"2006","unstructured":"Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155:709\u2013715","journal-title":"Eur J Endocrinol"},{"key":"1269_CR5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1210\/jc.2005-1602","volume":"91","author":"HD White","year":"2006","unstructured":"White HD, Ahmad AM, Durham BH et al (2006) Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 91:913\u2013919","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s001980200009","volume":"13","author":"S Minisola","year":"2002","unstructured":"Minisola S, Dionisi S, Pacitti MT et al (2002) Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 13:171\u2013175","journal-title":"Osteoporos Int"},{"key":"1269_CR7","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1210\/jc.2003-030772","volume":"88","author":"C Parkinson","year":"2003","unstructured":"Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650\u20135655","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1210\/jc.2016-3693","volume":"102","author":"T Constantin","year":"2017","unstructured":"Constantin T, Tangpricha V, Shah R et al (2017) Calcium and bone turnover markers in acromegaly: a prospective, controlled study. J Clin Endocrinol Metab 102:2416\u20132424. https:\/\/doi.org\/10.1210\/jc.2016-3693","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2265.2001.01280.x","volume":"55","author":"H Kaji","year":"2001","unstructured":"Kaji H, Sugimoto T, Nakaoka D et al (2001) Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf) 55:175\u2013181","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/EJE-10-1005","volume":"164","author":"MJ Wassenaar","year":"2011","unstructured":"Wassenaar MJ, Biermasz NR, Hamdy NA et al (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164:475\u2013483. https:\/\/doi.org\/10.1530\/EJE-10-1005","journal-title":"Eur J Endocrinol"},{"key":"1269_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/jc.2014-2937","volume":"100","author":"G Mazziotti","year":"2015","unstructured":"Mazziotti G, Biagioli E, Maffezzoni F et al (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100:384\u2013394. https:\/\/doi.org\/10.1210\/jc.2014-2937","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-16-0340","volume":"175","author":"K Godang","year":"2016","unstructured":"Godang K, Olarescu NC, Bollerslev J, Heck A (2016) Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol 175:155\u2013164. https:\/\/doi.org\/10.1530\/EJE-16-0340","journal-title":"Eur J Endocrinol"},{"key":"1269_CR13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00774-005-0649-9","volume":"24","author":"M Bolanowski","year":"2006","unstructured":"Bolanowski M, Daroszewski J, Medra\u015b M, Zadrozna-Sliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24:72\u201378","journal-title":"J Bone Miner Metab"},{"key":"1269_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01221-9","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Liu M, Chen H et al (2020) Associations between circulating bone-derived hormones lipocalin 2, osteocalcin, and glucose metabolism in acromegaly. J Endcrinol Investig. https:\/\/doi.org\/10.1007\/s40618-020-01221-9","journal-title":"J Endcrinol Investig"},{"key":"1269_CR15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/eje.0.1450685","volume":"145","author":"T Ueland","year":"2001","unstructured":"Ueland T, Bollerslev J, Godang K, M\u00fcller F, Fr\u00f8land SS, Aukrust P (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess\u2014possible role in bone homeostasis. Eur J Endocrinol 145:685\u2013690","journal-title":"Eur J Endocrinol"},{"key":"1269_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/bf00571329","volume":"52","author":"M Marazuela","year":"1993","unstructured":"Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Mar\u00edn F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52:419\u2013421. https:\/\/doi.org\/10.1007\/bf00571329","journal-title":"Calcif Tissue Int"},{"key":"1269_CR17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2007-1001672","volume":"26","author":"A Piovesan","year":"1994","unstructured":"Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res 26:234\u2013237","journal-title":"Horm Metab Res"},{"key":"1269_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1530\/EJE-18-0881","volume":"180","author":"M Ku\u017ema","year":"2019","unstructured":"Ku\u017ema M, Va\u0148uga P, S\u00e1gov\u00e1 I et al (2019) Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol 180:201\u2013211. https:\/\/doi.org\/10.1530\/EJE-18-0881","journal-title":"Eur J Endocrinol"},{"key":"1269_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1055\/a-0630-1529","volume":"50","author":"FF Ozer","year":"2018","unstructured":"Ozer FF, Dagdelen S, Erbas T (2018) Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma. Horm Metab Res 50:562\u2013567. https:\/\/doi.org\/10.1055\/a-0630-1529","journal-title":"Horm Metab Res"},{"key":"1269_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jocd.2007.03.103","volume":"10","author":"D Kastelan","year":"2007","unstructured":"Kastelan D, Dusek T, Kraljevic I et al (2007) Bone properties in patients with acromegaly: quantitative ultrasound of the heel. J Clin Densitom 10:327\u2013331. https:\/\/doi.org\/10.1016\/j.jocd.2007.03.103","journal-title":"J Clin Densitom"},{"key":"1269_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s001980200030","volume":"13","author":"M Bolanowski","year":"2002","unstructured":"Bolanowski M, Jedrzejuk D, Milewicz A, Arkowska A et al (2002) Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporos Int 13:303\u2013308. https:\/\/doi.org\/10.1007\/s001980200030","journal-title":"Osteoporos Int"},{"key":"1269_CR22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2265.2002.01624.x","volume":"57","author":"WP Fairfield","year":"2002","unstructured":"Fairfield WP, Sesmilo G, Katznelson L, Pulaski K et al (2002) Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf) 57:385\u2013390","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/BF03347998","volume":"20","author":"P Legovini","year":"1997","unstructured":"Legovini P, De Menis E, Breda F et al (1997) Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations. J Endocrinol Investig 20:434\u2013438. https:\/\/doi.org\/10.1007\/BF03347998","journal-title":"J Endocrinol Investig"},{"key":"1269_CR24","first-page":"1462","volume":"82","author":"AA Toogood","year":"1997","unstructured":"Toogood AA, Adams JE, O'Neill PA, Shalet SM (1997) Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 82:1462\u20131466","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1530\/eje.0.1370240","volume":"137","author":"T Ros\u00e9n","year":"1997","unstructured":"Ros\u00e9n T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240\u2013245","journal-title":"Eur J Endocrinol"},{"key":"1269_CR26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/8756-3282(96)00069-5","volume":"18","author":"N Bravenboer","year":"1996","unstructured":"Bravenboer N, Holzmann P, de Boer H, Blok GJ, Lips P (1996) Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 18:551\u2013557","journal-title":"Bone"},{"key":"1269_CR27","first-page":"1919","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Di Somma C, Pivonello R et al (1999) Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84:1919\u20131924","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S8756-3282(03)00240-0","volume":"33","author":"T Ueland","year":"2003","unstructured":"Ueland T, Odgren PR, Yndestad A et al (2003) Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency\u2013relationship with bone turn-over. Bone 33:638\u2013645","journal-title":"Bone"},{"key":"1269_CR29","first-page":"2143","volume":"83","author":"YJ Janssen","year":"1998","unstructured":"Janssen YJ, Hamdy NA, Fr\u00f6lich M, Roelfsema F (1998) Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 83:2143\u20132148","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/BF03345574","volume":"31","author":"F Rota","year":"2008","unstructured":"Rota F, Savanelli MC, Tauchmanova L et al (2008) Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Investig 31:94\u2013102. https:\/\/doi.org\/10.1007\/BF03345574","journal-title":"J Endocrinol Investig"},{"key":"1269_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF03343570","volume":"22","author":"S Longobardi","year":"1999","unstructured":"Longobardi S, Di Rella F, Pivonello R et al (1999) Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J Endocrinol Investig 22:333\u2013339. https:\/\/doi.org\/10.1007\/BF03343570","journal-title":"J Endocrinol Investig"},{"key":"1269_CR32","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1210\/jcem.82.6.3982","volume":"82","author":"N Bravenboer","year":"1997","unstructured":"Bravenboer N, Holzmann P, de Boer H et al (1997) The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab 82:1818\u20131822","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1359\/jbmr.2000.15.2.293","volume":"15","author":"K Brixen","year":"2000","unstructured":"Brixen K, Hansen TB, Hauge E et al (2000) Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: a 1-year, double-blind, randomized, placebo-controlled study. J Bone Miner Res 15:293\u2013300","journal-title":"J Bone Miner Res"},{"key":"1269_CR34","first-page":"2865","volume":"81","author":"G Johannsson","year":"1996","unstructured":"Johannsson G, Ros\u00e9n T, Bosaeus I, Sj\u00f6str\u00f6m L, Bengtsson BA (1996) Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 81:2865\u20132873","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF03343851","volume":"24","author":"A Sartorio","year":"2001","unstructured":"Sartorio A, Ortolani S, Galbiati E et al (2001) Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency. J Endocrinol Investig 24:224\u2013230","journal-title":"J Endocrinol Investig"},{"key":"1269_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.0.1460187","volume":"146","author":"SB Sneppen","year":"2002","unstructured":"Sneppen SB, Hoeck HC, Kollerup G et al (2002) Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults\u2014an 18-month randomised, placebo-controlled, double blinded trial. Eur J Endocrinol 146:187\u2013195","journal-title":"Eur J Endocrinol"},{"key":"1269_CR37","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1210\/jc.2002-021787","volume":"88","author":"AM Ahmad","year":"2003","unstructured":"Ahmad AM, Thomas J, Clewes A et al (2003) Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab 88:2860\u20132868","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR38","first-page":"3352","volume":"81","author":"TB Hansen","year":"1996","unstructured":"Hansen TB, Brixen K, Vahl N et al (1996) Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 81:3352\u20133359","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR39","first-page":"4104","volume":"85","author":"R Fernholm","year":"2000","unstructured":"Fernholm R, Bramnert M, H\u00e4gg E et al (2000) Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 85:4104\u20134112","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1530\/eje.0.1360282","volume":"136","author":"G Finkenstedt","year":"1997","unstructured":"Finkenstedt G, Gasser RW, H\u00f6fle G, Watfah C, Fridrich L (1997) Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol 136:282\u2013289","journal-title":"Eur J Endocrinol"},{"key":"1269_CR41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/eje.0.1400545","volume":"140","author":"MJ V\u00e4lim\u00e4ki","year":"1999","unstructured":"V\u00e4lim\u00e4ki MJ, Salmela PI, Salmi J et al (1999) Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 140:545\u2013554","journal-title":"Eur J Endocrinol"},{"key":"1269_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ghir.2013.12.001","volume":"24","author":"M Ku\u017ema","year":"2014","unstructured":"Ku\u017ema M, Ku\u017emov\u00e1 Z, Zelinkov\u00e1 Z et al (2014) Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res 24:22\u201328. https:\/\/doi.org\/10.1016\/j.ghir.2013.12.001","journal-title":"Growth Horm IGF Res"},{"key":"1269_CR43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2265.1995.tb02690.x","volume":"42","author":"SJ Holmes","year":"1995","unstructured":"Holmes SJ, Whitehouse RW, Swindell R et al (1995) Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol (Oxf) 42:627\u2013633","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s002239900392","volume":"62","author":"H Kotzmann","year":"1998","unstructured":"Kotzmann H, Riedl M, Bernecker P et al (1998) Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. Calcif Tissue Int 62:40\u201346","journal-title":"Calcif Tissue Int"},{"key":"1269_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1530\/eje.0.1480185","volume":"148","author":"R Lanzi","year":"2003","unstructured":"Lanzi R, Losa M, Villa I et al (2003) GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. Eur J Endocrinol 148:185\u2013191. https:\/\/doi.org\/10.1530\/eje.0.1480185","journal-title":"Eur J Endocrinol"},{"key":"1269_CR46","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1359\/jbmr.2002.17.6.1081","volume":"17","author":"M Bex","year":"2002","unstructured":"Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R (2002) The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 17:1081\u20131094. https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1081","journal-title":"J Bone Miner Res"},{"key":"1269_CR47","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1359\/JBMR.050613","volume":"20","author":"N Bravenboer","year":"2005","unstructured":"Bravenboer N, Holzmann PJ, ter Maaten JC et al (2005) Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 20:1778\u20131784","journal-title":"J Bone Miner Res"},{"key":"1269_CR48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2265.2005.02343.x","volume":"63","author":"LI Arwert","year":"2005","unstructured":"Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML (2005) Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 63:310\u2013316","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR49","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/cen.12493","volume":"81","author":"NM Appelman-Dijkstra","year":"2014","unstructured":"Appelman-Dijkstra NM, Claessen KM, Hamdy NA, Pereira AM, Biermasz NR (2014) Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf) 81:727\u2013735. https:\/\/doi.org\/10.1111\/cen.12493","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/EJE-15-1086","volume":"174","author":"NM Appelman-Dijkstra","year":"2016","unstructured":"Appelman-Dijkstra NM, Rijndorp M et al (2016) Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature. Eur J Endocrinol 174:705\u2013716. https:\/\/doi.org\/10.1530\/EJE-15-1086","journal-title":"Eur J Endocrinol"},{"key":"1269_CR51","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1210\/jc.2004-1650","volume":"90","author":"HD White","year":"2005","unstructured":"White HD, Ahmad AM, Durham BH et al (2005) Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients. J Clin Endocrinol Metab 90:3371\u20133380","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2265.2002.01582.x","volume":"57","author":"B Abrahamsen","year":"2002","unstructured":"Abrahamsen B, Hangaard J, Horn HC et al (2002) Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol (Oxf) 57:273\u2013281","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/er.2015-1106","volume":"37","author":"JH Bassett","year":"2016","unstructured":"Bassett JH, Williams GR (2016) Role of thyroid hormones in skeletal development and bone maintenance. Endocr Rev 37:135\u2013187. https:\/\/doi.org\/10.1210\/er.2015-1106","journal-title":"Endocr Rev"},{"key":"1269_CR54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/8756-3282(86)90681-2","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF, Mosekilde L, Melsen F (1986) Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle. Bone 7:101\u2013108","journal-title":"Bone"},{"key":"1269_CR55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/15287390252900340","volume":"65","author":"W Osterode","year":"2002","unstructured":"Osterode W, Zettinig G, P\u00f6tzi C, M\u00e4nner G (2002) Increased lead excretion in hypothyroid patients after levothyroxine medication. J Toxicol Environ Health A 65:649\u2013654","journal-title":"J Toxicol Environ Health A"},{"key":"1269_CR56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2265.1997.2351057.x","volume":"47","author":"L Persani","year":"1997","unstructured":"Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P (1997) Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol (Oxf) 47:207\u2013214","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1081\/ERC-100107181","volume":"27","author":"T Sabuncu","year":"2001","unstructured":"Sabuncu T, Aksoy N, Arikan E, Ugur B, Tasan E, Hatemi H (2001) Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism. Endocr Res 27:203\u2013213","journal-title":"Endocr Res"},{"key":"1269_CR58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02850169","volume":"23","author":"MR Sekeroglu","year":"2006","unstructured":"Sekeroglu MR, Altun ZB, Alg\u00fcn E (2006) Serum cytokines and bone metabolism in patients with thyroid dysfunction. Adv Ther 23:475\u2013480","journal-title":"Adv Ther"},{"key":"1269_CR59","first-page":"78","volume":"82","author":"P Lakatos","year":"1997","unstructured":"Lakatos P, Foldes J, Horvath C et al (1997) Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 82:78\u201381","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/BMI.S13965","volume":"9","author":"AL Christy","year":"2014","unstructured":"Christy AL, D'Souza V, Babu RP et al (2014) Utility of C-terminal telopeptide in evaluating levothyroxine replacement therapy-induced bone loss. Biomark Insights 9:1\u20136. https:\/\/doi.org\/10.4137\/BMI.S13965","journal-title":"Biomark Insights"},{"key":"1269_CR61","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1507\/endocrj.43.701","volume":"43","author":"M Miyakawa","year":"1996","unstructured":"Miyakawa M, Tsushima T, Demura H (1996) Carboxy-terminal propeptide of type 1 procollagen (P1CP) and carboxy-terminal telopeptide of type 1 collagen (1CTP) as sensitive markers of bone metabolism in thyroid disease. Endocr J 43:701\u2013708","journal-title":"Endocr J"},{"key":"1269_CR62","first-page":"56","volume":"86","author":"L Mosekilde","year":"1978","unstructured":"Mosekilde L, Melsen F (1978) Morphometric and dynamic studies of bone changes in hypothyroidism. Acta Pathol Microbiol Scand A 86:56\u201362","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"1269_CR63","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF03348786","volume":"15","author":"N Kojima","year":"1992","unstructured":"Kojima N, Sakata S, Nakamura S et al (1992) Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis. J Endocrinol Investig 15:491\u2013496","journal-title":"J Endocrinol Investig"},{"key":"1269_CR64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1507\/endocrj1954.35.121","volume":"35","author":"M Yoneda","year":"1988","unstructured":"Yoneda M, Takatsuki K, Yamauchi K et al (1988) Influence of thyroid function on serum bone Gla protein. Endocrinol Jpn 35:121\u2013129","journal-title":"Endocrinol Jpn"},{"key":"1269_CR65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-1009146","volume":"21","author":"P Bergmann","year":"1989","unstructured":"Bergmann P, Dediste A, Demeester-Mirkine N, Deconinck I, Corvilain J (1989) Serum bone Gla protein (BGP) in primary hypothyroidism before and during treatment with thyroid hormones. Horm Metab Res 21:47\u201348","journal-title":"Horm Metab Res"},{"key":"1269_CR66","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1055\/s-2007-1012275","volume":"18","author":"ME Martinez","year":"1986","unstructured":"Martinez ME, Herranz L, de Pedro C, Pallardo LF (1986) Osteocalcin levels in patients with hyper- and hypothyroidism. Horm Metab Res 18:212\u2013214","journal-title":"Horm Metab Res"},{"key":"1269_CR67","first-page":"BC08","volume":"10","author":"P Boruah","year":"2016","unstructured":"Boruah P, Baruah AJ, Hajong R et al (2016) A study to assess the validity of estimation of serum ostase level in hyperthyroid and hypothyroid cases. J Clin Diagn Res 10:BC08\u2013BC11","journal-title":"J Clin Diagn Res"},{"key":"1269_CR68","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1507\/endocrj.50.657","volume":"50","author":"G Kisakol","year":"2003","unstructured":"Kisakol G, Kaya A, Gonen S, Tunc R (2003) Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 50:657\u2013661","journal-title":"Endocr J"},{"key":"1269_CR69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/cen.13615","volume":"89","author":"R Siru","year":"2018","unstructured":"Siru R, Alfonso H, Chubb SAP, Golledge J, Flicker L, Yeap BB (2018) Subclinical thyroid dysfunction and circulating thyroid hormones are not associated with bone turnover markers or incident hip fracture in older men. Clin Endocrinol (Oxf) 89:93\u201399. https:\/\/doi.org\/10.1111\/cen.13615","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR70","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.arcmed.2005.09.009","volume":"37","author":"WY Lee","year":"2006","unstructured":"Lee WY, Oh KW, Rhee EJ et al (2006) Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 37:511\u2013516. https:\/\/doi.org\/10.1016\/j.arcmed.2005.09.009","journal-title":"Arch Med Res"},{"key":"1269_CR71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archinte.1986.00360130058007","volume":"146","author":"JM Coindre","year":"1986","unstructured":"Coindre JM, David JP, Rivi\u00e8re L et al (1986) Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med 146:48\u201353","journal-title":"Arch Intern Med"},{"key":"1269_CR72","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1530\/eje.0.1340702","volume":"134","author":"BL Langdahl","year":"1996","unstructured":"Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P (1996) Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. Eur J Endocrinol 134:702\u2013709. https:\/\/doi.org\/10.1530\/eje.0.1340702","journal-title":"Eur J Endocrinol"},{"key":"1269_CR73","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1210\/jcem-72-6-1189","volume":"72","author":"RD Harvey","year":"1991","unstructured":"Harvey RD, McHardy KC, Reid IW et al (1991) Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72:1189\u20131194","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR74","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/00016349609054714","volume":"75","author":"P Affinito","year":"1996","unstructured":"Affinito P, Sorrentino C, Farace MJ et al (1996) Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. Acta Obstet Gynecol Scand 75:843\u2013848","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1269_CR75","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2265.1997.1280950.x","volume":"46","author":"CY Guo","year":"1997","unstructured":"Guo CY, Weetman AP, Eastell R (1997) Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf) 46:301\u2013307","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR76","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1210\/clinem\/dgz058","volume":"105","author":"E Gonzalez Rodriguez","year":"2020","unstructured":"Gonzalez Rodriguez E, Stuber M, Del Giovane C et al (2020) Skeletal effects of levothyroxine for subclinical hypothyroidism in older adults: a TRUST randomized trial nested study. J Clin Endocrinol Metab 105:336\u2013343. https:\/\/doi.org\/10.1210\/clinem\/dgz058","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR77","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-003-1527-8","volume":"15","author":"C Meier","year":"2004","unstructured":"Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub JJ, Kraenzlin M (2004) Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 15:209\u2013216","journal-title":"Osteoporos Int"},{"key":"1269_CR78","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/eje.0.1380667","volume":"138","author":"J Toivonen","year":"1998","unstructured":"Toivonen J, T\u00e4htel\u00e4 R, Laitinen K, Risteli J, V\u00e4lim\u00e4ki MJ (1998) Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 138:667\u2013673","journal-title":"Eur J Endocrinol"},{"key":"1269_CR79","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1210\/jc.2012-2570","volume":"97","author":"R Schneider","year":"2012","unstructured":"Schneider R, Schneider M, Reiners C, Schneider P (2012) Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study. J Clin Endocrinol Metab 97:3926\u20133934. https:\/\/doi.org\/10.1210\/jc.2012-2570","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR80","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/thy.1997.7.561","volume":"7","author":"A Loviselli","year":"1997","unstructured":"Loviselli A, Mastinu R, Rizzolo E et al (1997) Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 7:561\u2013566. https:\/\/doi.org\/10.1089\/thy.1997.7.561","journal-title":"Thyroid"},{"key":"1269_CR81","first-page":"480","volume":"10","author":"I Karner","year":"2005","unstructured":"Karner I, Hrgovic Z, Sijanovic S et al (2005) Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res 10:480\u2013488","journal-title":"Eur J Med Res"},{"key":"1269_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/cen.12560","volume":"82","author":"S Tournis","year":"2015","unstructured":"Tournis S, Antoniou JD, Liakou CG et al (2015) Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol (Oxf) 82:197\u2013204. https:\/\/doi.org\/10.1111\/cen.12560","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.1997.12.1.72","volume":"12","author":"C Marcocci","year":"1997","unstructured":"Marcocci C, Golia F, Vignali E, Pinchera A (1997) Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 12:72\u201377. https:\/\/doi.org\/10.1359\/jbmr.1997.12.1.72","journal-title":"J Bone Miner Res"},{"key":"1269_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/eje.1.01933","volume":"153","author":"AC Heijckmann","year":"2005","unstructured":"Heijckmann AC, Huijberts MS, Geusens P, de Vries J, Menheere PP, Wolffenbuttel BH (2005) Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 153:23\u201329. https:\/\/doi.org\/10.1530\/eje.1.01933","journal-title":"Eur J Endocrinol"},{"key":"1269_CR85","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2016.0426","volume":"27","author":"M Ito","year":"2017","unstructured":"Ito M, Miyauchi A, Hisakado M et al (2017) (2017) Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid 27:484\u2013490. https:\/\/doi.org\/10.1089\/thy.2016.0426","journal-title":"Thyroid"},{"key":"1269_CR86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12020-010-9339-z","volume":"37","author":"JL Reverter","year":"2010","unstructured":"Reverter JL, Colom\u00e9 E, Holgado S et al (2010) Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma. Endocrine 37:467\u2013472. https:\/\/doi.org\/10.1007\/s12020-010-9339-z","journal-title":"Endocrine"},{"key":"1269_CR87","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/EJE-06-0649","volume":"156","author":"JI Botella-Carretero","year":"2007","unstructured":"Botella-Carretero JI, Alvarez-Blasco F, San Mill\u00e1n JL, Escobar-Morreale HF (2007) Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. Eur J Endocrinol 156:539\u2013545","journal-title":"Eur J Endocrinol"},{"key":"1269_CR88","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/thy.2006.0084","volume":"17","author":"C Regalbuto","year":"2007","unstructured":"Regalbuto C, Maiorana R, Alagona C et al (2007) Effects of either LT4 monotherapy or LT4\/LT3 combined therapy in patients totally thyroidectomized for thyroid cancer. Thyroid 17:323\u2013331. https:\/\/doi.org\/10.1089\/thy.2006.0084","journal-title":"Thyroid"},{"key":"1269_CR89","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1210\/jc.78.4.818","volume":"78","author":"C Marcocci","year":"1994","unstructured":"Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A (1994) Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78:818\u2013823. https:\/\/doi.org\/10.1210\/jc.78.4.818","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR90","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/105072503321669839","volume":"13","author":"P Mikosch","year":"2003","unstructured":"Mikosch P, Obermayer-Pietsch B, Jost R et al (2003) Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 13:347\u2013356","journal-title":"Thyroid"},{"key":"1269_CR91","doi-asserted-by":"publisher","first-page":"135","DOI":"10.11005\/jbm.2015.22.3.135","volume":"22","author":"CW Kim","year":"2015","unstructured":"Kim CW, Hong S, Oh SH et al (2015) Change of bone mineral density and biochemical markers of bone turnover in patients on suppressive levothyroxine therapy for differentiated thyroid carcinoma. J Bone Metab 22:135\u2013141. https:\/\/doi.org\/10.11005\/jbm.2015.22.3.135","journal-title":"J Bone Metab"},{"key":"1269_CR92","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.surg.2018.10.034","volume":"165","author":"SG Iglesias","year":"2019","unstructured":"Iglesias SG, Dominguez MLM, Herrero EF et al (2019) Trabecular bone score and bone mineral density in patients with postsurgical hypoparathyroidism after total thyroidectomy for differentiated thyroid carcinoma. Surgery 165:814\u2013819. https:\/\/doi.org\/10.1016\/j.surg.2018.10.034","journal-title":"Surgery"},{"key":"1269_CR93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF03349174","volume":"29","author":"C Regalbuto","year":"2006","unstructured":"Regalbuto C, Alagona C, Maiorana R et al (2006) Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer. J Endocrinol Investig 29:32\u201340","journal-title":"J Endocrinol Investig"},{"key":"1269_CR94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/edrv-7-4-379","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379\u2013408","journal-title":"Endocr Rev"},{"key":"1269_CR95","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/8756-3282(85)90218-2","volume":"6","author":"EF Eriksen","year":"1985","unstructured":"Eriksen EF, Mosekilde L, Melsen F (1985) Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 6:421\u2013428","journal-title":"Bone"},{"key":"1269_CR96","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bone.2004.04.021","volume":"35","author":"G Amato","year":"2004","unstructured":"Amato G, Mazziotti G, Sorvillo F et al (2004) High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 35:785\u2013791","journal-title":"Bone"},{"key":"1269_CR97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2265.2002.01578.x","volume":"57","author":"A Akalin","year":"2002","unstructured":"Akalin A, Colak O, Alatas O, Efe B (2002) Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf) 57:125\u2013129","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00774-003-0455-1","volume":"22","author":"MN Ak\u00e7ay","year":"2004","unstructured":"Ak\u00e7ay MN, Ak\u00e7ay G, BIlen H (2004) The effects of calcitonin on bone resorption in hyperthyroidism: a placebo-controlled clinical study. J Bone Miner Metab 22:90\u201393. https:\/\/doi.org\/10.1007\/s00774-003-0455-1","journal-title":"J Bone Miner Metab"},{"key":"1269_CR99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4158\/EP.12.2.121","volume":"12","author":"KA Al-Shoumer","year":"2006","unstructured":"Al-Shoumer KA, Vasanthy BA, Al-Zaid MM (2006) Effects of treatment of hyperthyroidism on glucose homeostasis, insulin secretion, and markers of bone turnover. Endocr Pract 12:121\u2013130","journal-title":"Endocr Pract"},{"key":"1269_CR100","first-page":"461","volume":"16","author":"P Arbault","year":"1995","unstructured":"Arbault P, Grimaux M, Pradet V, Preaudat C, Seguin P, Delmas PD (1995) Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone 16:461\u2013467","journal-title":"Bone"},{"key":"1269_CR101","doi-asserted-by":"publisher","first-page":"BC11","DOI":"10.7860\/JCDR\/2019\/41445.13011","volume":"13","author":"SH Mhaibes","year":"2019","unstructured":"Mhaibes SH, Ameen IA, Saleh ES, Taha KN, Kamil HS (2019) Impact of hyperthyroidism on biochemical markers of bone metabolism. J Clin Diagn Res 13:BC11\u2013BC14. https:\/\/doi.org\/10.7860\/JCDR\/2019\/41445.13011","journal-title":"J Clin Diagn Res"},{"key":"1269_CR102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000182315","volume":"37","author":"E De Menis","year":"1992","unstructured":"De Menis E, Da Rin G, Roiter I, Legovini P, Foscolo G, Conte N (1992) Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm Res 37:217\u2013220","journal-title":"Horm Res"},{"key":"1269_CR103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1472-6823-11-15","volume":"11","author":"HM El Hadidy","year":"2011","unstructured":"El Hadidy HM, Ghonaim M, El Gawad SSh, El Atta MA (2011) Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMC Endocr Disord 11:15. https:\/\/doi.org\/10.1186\/1472-6823-11-15","journal-title":"BMC Endocr Disord"},{"key":"1269_CR104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0009-8981(99)00173-4","volume":"289","author":"H Engler","year":"1999","unstructured":"Engler H, Oettli RE, Riesen WF (1999) Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study. Clin Chim Acta 289:159\u2013172","journal-title":"Clin Chim Acta"},{"key":"1269_CR105","first-page":"955","volume":"78","author":"P Garnero","year":"1994","unstructured":"Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD (1994) Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 78:955\u2013959","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR106","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03345061","volume":"23","author":"GC Isaia","year":"2000","unstructured":"Isaia GC, Roggia C, Gola D et al (2000) Bone turnover in hyperthyroidism before and after thyrostatic management. J Endocrinol Investig 23:727\u2013731","journal-title":"J Endocrinol Investig"},{"key":"1269_CR107","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1055\/s-2007-1001698","volume":"26","author":"P Legovini","year":"1994","unstructured":"Legovini P, De Menis E, Da Rin G et al (1994) Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism. Horm Metab Res 26:334\u2013337. https:\/\/doi.org\/10.1055\/s-2007-1001698","journal-title":"Horm Metab Res"},{"key":"1269_CR108","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/jcem-70-3-766","volume":"70","author":"MS Lee","year":"1990","unstructured":"Lee MS, Kim SY, Lee MC et al (1990) Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 70:766\u2013770","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR109","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2265.1997.2401045.x","volume":"47","author":"S Nagasaka","year":"1997","unstructured":"Nagasaka S, Sugimoto H, Nakamura T et al (1997) Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 47:215\u2013221","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/8756-3282(94)90885-0","volume":"15","author":"T Ohishi","year":"1994","unstructured":"Ohishi T, Kushida K, Takahashi M et al (1994) Urinary bone resorption markers in patients with metabolic bone disorders. Bone 15:15\u201320","journal-title":"Bone"},{"key":"1269_CR111","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejim.2006.12.010","volume":"18","author":"T Psaltopoulou","year":"2007","unstructured":"Psaltopoulou T, Ilias I, Toumanidis S et al (2007) Endogenous subclinical hyperthyroidism: metabolic and cardiac parameters. Eur J Intern Med 18:423\u2013429. https:\/\/doi.org\/10.1016\/j.ejim.2006.12.010","journal-title":"Eur J Intern Med"},{"key":"1269_CR112","first-page":"753","volume":"82","author":"A Siddiqi","year":"1997","unstructured":"Siddiqi A, Burrin JM, Noonan K et al (1997) A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 82:753\u2013759","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR113","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1210\/jcem.82.6.4026","volume":"82","author":"E J\u00f3dar","year":"1997","unstructured":"J\u00f3dar E, Mu\u00f1oz-Torres M, Escobar-Jim\u00e9nez F et al (1997) Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 82:1989\u20131994","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/clin.1995.1075","volume":"75","author":"C Wenisch","year":"1995","unstructured":"Wenisch C, Bankl HC, Sch\u00f6nthal E et al (1995) Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopathol 75:225\u2013230","journal-title":"Clin Immunol Immunopathol"},{"key":"1269_CR115","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1590\/S0004-27302008000900007","volume":"52","author":"PW Rosario","year":"2008","unstructured":"Rosario PW (2008) Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arq Bras Endocrinol Metabol 52:1448\u20131451","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1269_CR116","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.maturitas.2004.02.017","volume":"48","author":"L Tauchmanov\u00e0","year":"2004","unstructured":"Tauchmanov\u00e0 L, Nuzzo V, Del Puente A et al (2004) Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 48:299\u2013306","journal-title":"Maturitas"},{"key":"1269_CR117","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1447-0756.2009.01132.x","volume":"36","author":"KH Ahn","year":"2010","unstructured":"Ahn KH, Lee SH, Park HT et al (2010) Effect of adiponectin and sex steroid hormones on bone mineral density and bone formation markers in postmenopausal women with subclinical hyperthyroidism. J Obstet Gynaecol Res 36:370\u2013376. https:\/\/doi.org\/10.1111\/j.1447-0756.2009.01132.x","journal-title":"J Obstet Gynaecol Res"},{"key":"1269_CR118","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cen.12979","volume":"85","author":"PW Rosario","year":"2016","unstructured":"Rosario PW, Carvalho M, Calsolari MR (2016) Symptoms of thyrotoxicosis, bone metabolism and occult atrial fibrillation in older women with mild endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 85:132\u2013136. https:\/\/doi.org\/10.1111\/cen.12979","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR119","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/thy.1999.9.539","volume":"9","author":"A G\u00fcrlek","year":"1999","unstructured":"G\u00fcrlek A, Gedik O (1999) Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 9:539\u2013543. https:\/\/doi.org\/10.1089\/thy.1999.9.539","journal-title":"Thyroid"},{"key":"1269_CR120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1620\/tjem.203.183","volume":"203","author":"G Barsal","year":"2004","unstructured":"Barsal G, Taneli F, Atay A, Hekimsoy Z, Erciyas F (2004) Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy. Tohoku J Exp Med 203:183\u2013188","journal-title":"Tohoku J Exp Med"},{"key":"1269_CR121","first-page":"4157","volume":"85","author":"Y Kumeda","year":"2000","unstructured":"Kumeda Y, Inaba M, Tahara H et al (2000) Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157\u20134161","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2265.1999.00626.x","volume":"50","author":"M Olkawa","year":"1999","unstructured":"Olkawa M, Kushida K, Takahashi M et al (1999) Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol (Oxf) 50:171\u2013176","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR123","first-page":"428","volume":"66","author":"AC van de Ven","year":"2008","unstructured":"van de Ven AC, Erdtsieck RJ (2008) Changes of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism. Neth J Med 66:428\u2013432","journal-title":"Neth J Med"},{"key":"1269_CR124","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/JCD:7:2:201","volume":"7","author":"CG Acotto","year":"2004","unstructured":"Acotto CG, Niepomniszcze H, Vega E, Mautalen CA (2004) Ultrasound parameters and markers of bone turnover in hyperthyroidism: a longitudinal study. J Clin Densitom 7:201\u2013208","journal-title":"J Clin Densitom"},{"key":"1269_CR125","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1210\/jcem.85.3.6457","volume":"85","author":"H Pantazi","year":"2000","unstructured":"Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099\u20131106","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR126","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/000456329603300510","volume":"33","author":"H Wilkinson","year":"1996","unstructured":"Wilkinson H, Horsely E (1996) Changes in markers of bone collagen turnover in toxic and euthyroid states: a study of 22 patients. Ann Clin Biochem 33:454\u2013455","journal-title":"Ann Clin Biochem"},{"key":"1269_CR127","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1365-2265.2011.04295.x","volume":"76","author":"BJ Schouten","year":"2012","unstructured":"Schouten BJ, Prickett TC, Hunt PJ et al (2012) C-type natriuretic peptide forms in adult hyperthyroidism: correlation with thyroid hormones and markers of bone turnover. Clin Endocrinol (Oxf) 76:790\u2013796. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04295.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR128","doi-asserted-by":"crossref","first-page":"706","DOI":"10.7326\/0003-4819-139-8-200310210-00027","volume":"139","author":"M Grieff","year":"2003","unstructured":"Grieff M (2003) The hungry bone syndrome after medical treatment of thyrotoxicosis. Ann Intern Med 139:706\u2013707","journal-title":"Ann Intern Med"},{"key":"1269_CR129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/8756-3282(95)80020-Q","volume":"16","author":"H Brockstedt","year":"1995","unstructured":"Brockstedt H, Christiansen P, Mosekilde L, Melsen F (1995) Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery. Bone 16:109\u2013117","journal-title":"Bone"},{"key":"1269_CR130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/8756-3282(92)90360-9","volume":"13","author":"P Christiansen","year":"1992","unstructured":"Christiansen P, Steiniche T, Vesterby A, Mosekilde L, Hessov I, Melsen F (1992) Primary hyperparathyroidism: iliac crest trabecular bone volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone 13:41\u201349","journal-title":"Bone"},{"key":"1269_CR131","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/8756-3282(86)90020-7","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF, Mosekilde L, Melsen F (1986) Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone 7:213\u2013221","journal-title":"Bone"},{"key":"1269_CR132","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI112400","volume":"77","author":"PD Delmas","year":"1986","unstructured":"Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ (1986) Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Investig 77:985\u2013991","journal-title":"J Clin Investig"},{"key":"1269_CR133","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0169-6009(08)80100-6","volume":"23","author":"L van Doorn","year":"1993","unstructured":"van Doorn L, Lips P, Netelenbos JC, Hackeng WH (1993) Bone histomorphometry and serum concentrations of intact parathyroid hormone (PTH(1\u201384)) in patients with primary hyperparathyroidism. Bone Miner 23:233\u2013242","journal-title":"Bone Miner"},{"key":"1269_CR134","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/8756-3282(93)90207-Q","volume":"14","author":"P Christiansen","year":"1993","unstructured":"Christiansen P, Steiniche T, Brockstedt H, Mosekilde L, Hessov I, Melsen F (1993) Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone 14:755\u2013762","journal-title":"Bone"},{"key":"1269_CR135","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","volume":"92","author":"H Lowe","year":"2007","unstructured":"Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001\u20133005","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR136","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","volume":"88","author":"G Maruani","year":"2003","unstructured":"Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88:4641\u20134648","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR137","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00268-002-6649-1","volume":"27","author":"A Bergenfelz","year":"2003","unstructured":"Bergenfelz A, Lindblom P, Linderg\u00e5rd B, Valdemarsson S, Westerdahl J (2003) Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism. World J Surg 27:481\u2013485","journal-title":"World J Surg"},{"key":"1269_CR138","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjsurg.2019.10.032","volume":"219","author":"J G\u00f3mez-Ram\u00edrez","year":"2020","unstructured":"G\u00f3mez-Ram\u00edrez J, G\u00f3mez-Valdazo A, Luengo P, Porrero B, Osorio I, Rivas S (2020) Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? Am J Surg 219:150\u2013153. https:\/\/doi.org\/10.1016\/j.amjsurg.2019.10.032","journal-title":"Am J Surg"},{"key":"1269_CR139","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa174","author":"A Palermo","year":"2020","unstructured":"Palermo A, Naciu AM, Tabacco G et al (2020) Clinical, biochemical and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa174","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR140","doi-asserted-by":"publisher","first-page":"7617254","DOI":"10.1155\/2019\/7617254","volume":"2019","author":"C Aresta","year":"2019","unstructured":"Aresta C, Passeri E, Corbetta S (2019) Symptomatic hypercalcemia in patients with primary hyperparathyroidism is associated with severity of disease, polypharmacy, and comorbidity. Int J Endocrinol 2019:7617254. https:\/\/doi.org\/10.1155\/2019\/7617254","journal-title":"Int J Endocrinol"},{"key":"1269_CR141","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","volume":"88","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Lee KH, McMahon DJ, Silverberg SJ (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:1174\u20131178","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR142","first-page":"723","volume":"80","author":"SJ Silverberg","year":"1995","unstructured":"Silverberg SJ, Gartenberg F, Jacobs TP et al (1995) Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 80:723\u2013728","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR143","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jocd.2008.11.005","volume":"12","author":"F Bandeira","year":"2009","unstructured":"Bandeira F, Griz LH, Bandeira C et al (2009) Prevalence of cortical osteoporosis in mild and severe primary hyperparathyroidism and its relationship with bone markers and vitamin D status. J Clin Densitom 12:195\u2013199. https:\/\/doi.org\/10.1016\/j.jocd.2008.11.005","journal-title":"J Clin Densitom"},{"key":"1269_CR144","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S8756-3282(98)00042-8","volume":"22","author":"S Adami","year":"1998","unstructured":"Adami S, Braga V, Squaranti R, Rossini M, Gatti D, Zamberlan N (1998) Bone measurements in asymptomatic primary hyperparathyroidism. Bone 22:565\u2013570","journal-title":"Bone"},{"key":"1269_CR145","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/cen.12732","volume":"82","author":"A Palermo","year":"2015","unstructured":"Palermo A, Jacques R, Gossiel F et al (2015) Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The OPUS study. Clin Endocrinol (Oxf) 82:816\u2013823. https:\/\/doi.org\/10.1111\/cen.12732","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR146","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/jbmr.3177","volume":"32","author":"K Lundstam","year":"2017","unstructured":"Lundstam K, Heck A, Godang K et al (2017) Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study). J Bone Miner Res 32:1907\u20131914. https:\/\/doi.org\/10.1002\/jbmr.3177","journal-title":"J Bone Miner Res"},{"key":"1269_CR147","first-page":"780","volume":"79","author":"P Garnero","year":"1994","unstructured":"Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780\u2013785","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR148","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF03348019","volume":"20","author":"S Minisola","year":"1997","unstructured":"Minisola S, Pacitti MT, Rosso R et al (1997) The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism. J Endocrinol Investig 20:559\u2013565","journal-title":"J Endocrinol Investig"},{"key":"1269_CR149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00365519409086504","volume":"54","author":"C De la Piedra","year":"1994","unstructured":"De la Piedra C, D\u00edaz Mart\u00edn MA, D\u00edaz Diego EM et al (1994) Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction. Scand J Clin Lab Investig 54:11\u201315","journal-title":"Scand J Clin Lab Investig"},{"key":"1269_CR150","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/a-0850-8679","volume":"51","author":"GA Miguel","year":"2019","unstructured":"Miguel GA, Carranza FH, Rodr\u00edguez JCR et al (2019) Trabecular bone score, bone mineral density and bone markers in patients with primary hyperparathyroidism 2 years after parathyroidectomy. Horm Metab Res 51:186\u2013190. https:\/\/doi.org\/10.1055\/a-0850-8679","journal-title":"Horm Metab Res"},{"key":"1269_CR151","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1308\/rcsann.2017.0092","volume":"99","author":"P Rajeev","year":"2017","unstructured":"Rajeev P, Movseysan A, Baharani A (2017) Changes in bone turnover markers in primary hyperparathyroidism and response to surgery. Ann R Coll Surg Engl 99:559\u2013562. https:\/\/doi.org\/10.1308\/rcsann.2017.0092","journal-title":"Ann R Coll Surg Engl"},{"key":"1269_CR152","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1420451","volume":"142","author":"CY Guo","year":"2000","unstructured":"Guo CY, Holland PA, Jackson BF et al (2000) Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol 142:451\u2013459","journal-title":"Eur J Endocrinol"},{"key":"1269_CR153","first-page":"3487","volume":"81","author":"CY Guo","year":"1996","unstructured":"Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R (1996) Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3487\u20133491","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR154","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/PL00005815","volume":"64","author":"S Minisola","year":"1999","unstructured":"Minisola S, Pacitti MT, Romagnoli E et al (1999) Clinical validation of a new immunoradiometric assay for intact human osteocalcin. Calcif Tissue Int 64:365\u2013369","journal-title":"Calcif Tissue Int"},{"key":"1269_CR155","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3275\/7923","volume":"35","author":"S Alonso","year":"2012","unstructured":"Alonso S, Ferrero E, Donat M et al (2012) The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy. J Endocrinol Investig 35:640\u2013644. https:\/\/doi.org\/10.3275\/7923","journal-title":"J Endocrinol Investig"},{"key":"1269_CR156","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/jcem-66-5-951","volume":"66","author":"RJ Duda Jr","year":"1988","unstructured":"Duda RJ Jr, O'Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL (1988) Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951\u2013957","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR157","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2006-944533","volume":"38","author":"H Kaji","year":"2006","unstructured":"Kaji H, Nomura R, Yamauchi M, Chihara K, Sugimoto T (2006) The usefulness of bone metabolic indices for the prediction of changes in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism. Horm Metab Res 38:411\u2013416","journal-title":"Horm Metab Res"},{"key":"1269_CR158","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","volume":"14","author":"HW Woitge","year":"1999","unstructured":"Woitge HW, Pecherstorfer M, Li Y et al (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792\u2013801","journal-title":"J Bone Miner Res"},{"key":"1269_CR159","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/00365519109104560","volume":"51","author":"L Scarnecchia","year":"1991","unstructured":"Scarnecchia L, Minisola S, Pacitti MT et al (1991) Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Investig 51:517\u2013524","journal-title":"Scand J Clin Lab Investig"},{"key":"1269_CR160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1507\/endocrj1954.35.39","volume":"35","author":"M Yoneda","year":"1988","unstructured":"Yoneda M, Takatsuki K, Yamauchi K et al (1988) Effect of parathyroid function on serum bone Gla protein. Endocrinol Jpn 35:39\u201345","journal-title":"Endocrinol Jpn"},{"key":"1269_CR161","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S8756-3282(97)00078-1","volume":"21","author":"P Christiansen","year":"1997","unstructured":"Christiansen P, Steiniche T, Brixen K et al (1997) Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21:93\u201399","journal-title":"Bone"},{"key":"1269_CR162","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","volume":"39","author":"A Faggiano","year":"2011","unstructured":"Faggiano A, Di Somma C, Ramundo V et al (2011) Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 39:283\u2013287. https:\/\/doi.org\/10.1007\/s12020-011-9459-0","journal-title":"Endocrine"},{"key":"1269_CR163","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0169-6009(91)90143-N","volume":"8","author":"D Uebelhart","year":"1990","unstructured":"Uebelhart D, Gineyts E, Chapuy MC, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87\u201396","journal-title":"Bone Miner"},{"key":"1269_CR164","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(90)90053-2","volume":"11","author":"P Christiansen","year":"1990","unstructured":"Christiansen P, Steiniche T, Mosekilde L, Hessov I, Melsen F (1990) Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment-evaluated by histomorphometric methods. Bone 11:75\u201379","journal-title":"Bone"},{"key":"1269_CR165","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S8756-3282(00)00260-X","volume":"26","author":"T Steiniche","year":"2000","unstructured":"Steiniche T, Christiansen P, Vesterby A et al (2000) Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone 26:535\u2013543","journal-title":"Bone"},{"key":"1269_CR166","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1098-2388(199703\/04)13:2<125::AID-SSU8>3.0.CO;2-B","volume":"13","author":"Y Tanaka","year":"1997","unstructured":"Tanaka Y, Funahashi H, Imai T, Tominaga Y, Takagi H (1997) Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 13:125\u2013133","journal-title":"Semin Surg Oncol"},{"key":"1269_CR167","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2265.2000.00900.x","volume":"52","author":"Y Abe","year":"2000","unstructured":"Abe Y, Ejima E, Fujiyama K et al (2000) Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol (Oxf) 52:203\u2013209","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR168","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/BF03343897","volume":"24","author":"V Carnevale","year":"2001","unstructured":"Carnevale V, Pacitti MT, Pileri M et al (2001) Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. J Endocrinol Investig 24:575\u2013579","journal-title":"J Endocrinol Investig"},{"key":"1269_CR169","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(99)00150-7","volume":"25","author":"P Christiansen","year":"1999","unstructured":"Christiansen P, Steiniche T, Brixen K et al (1999) Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 25:237\u2013244","journal-title":"Bone"},{"key":"1269_CR170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2796.1998.00241.x","volume":"243","author":"S Valdemarsson","year":"1998","unstructured":"Valdemarsson S, Linderg\u00e5rd B, Tibblin S, Bergenfelz A (1998) Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J Intern Med 243:115\u2013122","journal-title":"J Intern Med"},{"key":"1269_CR171","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00774-007-0754-z","volume":"25","author":"Y Tamura","year":"2007","unstructured":"Tamura Y, Araki A, Chiba Y, Mori S, Hosoi T, Horiuchi T (2007) Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab 25:226\u2013231. https:\/\/doi.org\/10.1007\/s00774-007-0754-z","journal-title":"J Bone Miner Metab"},{"key":"1269_CR172","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.surg.2004.06.059","volume":"136","author":"EG Almqvist","year":"2004","unstructured":"Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J (2004) Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study. Surgery 136:1281\u20131288. https:\/\/doi.org\/10.1016\/j.surg.2004.06.059","journal-title":"Surgery"},{"key":"1269_CR173","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00223-002-2100-8","volume":"73","author":"LS Stilgren","year":"2003","unstructured":"Stilgren LS, Heged\u00fcs LM, Beck-Nielsen H, Abrahamsen B (2003) Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int 73:210\u2013216. https:\/\/doi.org\/10.1007\/s00223-002-2100-8","journal-title":"Calcif Tissue Int"},{"key":"1269_CR174","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2265.1995.tb02668.x","volume":"42","author":"M Garton","year":"1995","unstructured":"Garton M, Martin J, Stewart A et al (1995) Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. Clin Endocrinol (Oxf) 42:493\u2013500","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR175","doi-asserted-by":"publisher","first-page":"394","DOI":"10.20945\/2359-3997000000154","volume":"63","author":"MN Ohe","year":"2019","unstructured":"Ohe MN, Bonans\u00e9a TCP, Santos RO et al (2019) Prediction of bone mass changes after successful parathyroidectomy using biochemical markers of bone metabolism in primary hyperparathyroidism: is it clinically useful? Arch Endocrinol Metab 63:394\u2013401. https:\/\/doi.org\/10.20945\/2359-3997000000154","journal-title":"Arch Endocrinol Metab"},{"key":"1269_CR176","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","volume":"88","author":"CC Chow","year":"2003","unstructured":"Chow CC, Chan WB, Li JK et al (2003) Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:581\u2013587","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR177","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","volume":"160","author":"BJ Orr-Walker","year":"2000","unstructured":"Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR (2000) Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 160:2161\u20132166","journal-title":"Arch Intern Med"},{"key":"1269_CR178","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00223-011-9489-x","volume":"89","author":"M Rossini","year":"2011","unstructured":"Rossini M, Viapiana O, Kalpakcioglu B et al (2011) Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism. Calcif Tissue Int 89:21\u201328. https:\/\/doi.org\/10.1007\/s00223-011-9489-x","journal-title":"Calcif Tissue Int"},{"key":"1269_CR179","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1210\/jc.2003-030908","volume":"89","author":"AA Khan","year":"2004","unstructured":"Khan AA, Bilezikian JP, Kung AW et al (2004) (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:3319\u20133325. https:\/\/doi.org\/10.1210\/jc.2003-030908","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR180","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","volume":"26","author":"R Cesareo","year":"2015","unstructured":"Cesareo R, Di Stasio E, Vescini F et al (2015) Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 26:1295\u20131302. https:\/\/doi.org\/10.1007\/s00198-014-3000-2","journal-title":"Osteoporos Int"},{"key":"1269_CR181","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135\u2013141","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR182","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","volume":"92","author":"SJ Silverberg","year":"2007","unstructured":"Silverberg SJ, Rubin MR, Faiman C et al (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803\u20133808","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR183","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1210\/jc.2010-1221","volume":"96","author":"M Peacock","year":"2011","unstructured":"Peacock M, Bilezikian JP, Bolognese MA et al (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 96:E9\u201318. https:\/\/doi.org\/10.1210\/jc.2010-1221","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR184","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3275\/7970","volume":"35","author":"F Cetani","year":"2012","unstructured":"Cetani F, Saponaro F, Banti C et al (2012) Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Investig 35:655\u2013660. https:\/\/doi.org\/10.3275\/7970","journal-title":"J Endocrinol Investig"},{"key":"1269_CR185","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1210\/jc.2008-2640","volume":"94","author":"C Marcocci","year":"2019","unstructured":"Marcocci C, Chanson P, Shoback D et al (2019) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 94:2766\u20132772. https:\/\/doi.org\/10.1210\/jc.2008-2640","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR186","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1002\/jbmr.452","volume":"26","author":"MR Rubin","year":"2011","unstructured":"Rubin MR, Dempster DW, Sliney J Jr et al (2011) PTH(1\u201384) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 26:2727\u20132736. https:\/\/doi.org\/10.1002\/jbmr.452","journal-title":"J Bone Miner Res"},{"key":"1269_CR187","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1507\/endocrj1954.35.39","volume":"35","author":"M Yoneda","year":"1988","unstructured":"Yoneda M, Takatsuki K, Yamauchi K et al (1988) Tomita A. Effect of parathyroid function on serum bone Gla protein. Endocrinol Jpn 35:39\u201345","journal-title":"Endocrinol Jpn"},{"key":"1269_CR188","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1172\/JCI113690","volume":"82","author":"K Mizunashi","year":"1988","unstructured":"Mizunashi K, Furukawa Y, Miura R, Yumita S, Sohn HE, Yoshinaga K (1988) Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism. J Clin Investig 82:861\u2013865","journal-title":"J Clin Investig"},{"key":"1269_CR189","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin MR, Dempster DW, Zhou H et al (2008) Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23:2018\u20132024. https:\/\/doi.org\/10.1359\/jbmr.080803","journal-title":"J Bone Miner Res"},{"key":"1269_CR190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/8756-3282(95)00443-2","volume":"18","author":"BL Langdahl","year":"1996","unstructured":"Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P (1996) Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 18:103\u2013108","journal-title":"Bone"},{"key":"1269_CR191","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/jbmr.3543","volume":"33","author":"MR Rubin","year":"2018","unstructured":"Rubin MR, Zhou H, Cusano NE et al (2018) The effects of long-term administration of rhPTH(1\u201384) in hypoparathyroidism by bone histomorphometry. J Bone Miner Res 33:1931\u20131939. https:\/\/doi.org\/10.1002\/jbmr.3543","journal-title":"J Bone Miner Res"},{"key":"1269_CR192","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L (2011) Hypoparathyroid Study Group. The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 26:2358\u20132370. https:\/\/doi.org\/10.1002\/jbmr.470","journal-title":"J Bone Miner Res"},{"key":"1269_CR193","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1210\/jc.2019-01010","volume":"104","author":"M Mannstadt","year":"2019","unstructured":"Mannstadt M, Clarke BL, Bilezikian JP et al (2019) Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab 104:5136\u20135147. https:\/\/doi.org\/10.1210\/jc.2019-01010","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR194","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ et al (2013) Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 98:137\u2013144. https:\/\/doi.org\/10.1210\/jc.2012-2984","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR195","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1210\/jc.2015-4135","volume":"101","author":"MR Rubin","year":"2016","unstructured":"Rubin MR, Cusano NE, Fan WW et al (2016) Therapy of Hypoparathyroidism With PTH(1\u201384): A Prospective Six Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab 101:2742\u20132750. https:\/\/doi.org\/10.1210\/jc.2015-4135","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR196","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","volume":"88","author":"KK Winer","year":"2003","unstructured":"Winer KK, Ko CW, Reynolds JC et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1\u201334) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214\u20134220","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR197","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jc.2011-1908","volume":"97","author":"KK Winer","year":"2012","unstructured":"Winer KK, Zhang B, Shrader JA et al (2012) Synthetic human parathyroid hormone 1\u201334 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97:391\u2013399. https:\/\/doi.org\/10.1210\/jc.2011-1908","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR198","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.2555","volume":"30","author":"RI Gafni","year":"2015","unstructured":"Gafni RI, Guthrie LC, Kelly MH et al (2015) Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1\u201334 (hPTH 1\u201334) replacement therapy in hypoparathyroidism. J Bone Miner Res 30:2112\u20132118. https:\/\/doi.org\/10.1002\/jbmr.2555","journal-title":"J Bone Miner Res"},{"key":"1269_CR199","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","volume":"276","author":"KK Winer","year":"1996","unstructured":"Winer KK, Yanovski JA, Cutler GB Jr (1996) Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276:631\u2013636","journal-title":"JAMA"},{"key":"1269_CR200","doi-asserted-by":"publisher","unstructured":"CORRIGENDUM FOR 10.1210\/jc.2011-1908 (2015) J Clin Endocrinol Metab 100:2800. https:\/\/doi.org\/10.1210\/jc.2015-2347","DOI":"10.1210\/jc.2015-2347"},{"key":"1269_CR201","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jcem-59-3-394","volume":"59","author":"WM Law Jr","year":"1984","unstructured":"Law WM Jr, Heath H 3rd (1984) Increased renal responses to exogenous parathyroid hormone in postsurgical hypoparathyroidism. J Clin Endocrinol Metab 59:394\u2013397","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR202","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00198-009-0978-y","volume":"21","author":"A Szappanos","year":"2010","unstructured":"Szappanos A, Toke J, Lippai D et al (2010) Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment. Osteoporos Int 21:637\u2013645. https:\/\/doi.org\/10.1007\/s00198-009-0978-y","journal-title":"Osteoporos Int"},{"key":"1269_CR203","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","volume":"25","author":"L Trementino","year":"2014","unstructured":"Trementino L, Appolloni G, Ceccoli L et al (2014) Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 25:913\u2013921. https:\/\/doi.org\/10.1007\/s00198-013-2520-5","journal-title":"Osteoporos Int"},{"key":"1269_CR204","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/0300060517725660","volume":"46","author":"W Guo","year":"2018","unstructured":"Guo W, Li F, Zhu C et al (2018) Effect of hypercortisolism on bone mineral density and bone metabolism: a potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease. J Int Med Res 46:492\u2013503. https:\/\/doi.org\/10.1177\/0300060517725660","journal-title":"J Int Med Res"},{"key":"1269_CR205","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1210\/jc.2005-0582","volume":"91","author":"L Tauchmanov\u00e0","year":"2006","unstructured":"Tauchmanov\u00e0 L, Pivonello R, Di Somma C et al (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779\u20131784","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR206","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2796.1996.416763000.x","volume":"239","author":"H Dobnig","year":"1996","unstructured":"Dobnig H, Stepan V, Leb G, Wolf G, Buchfelder M, Krejs GJ (1996) Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid. J Intern Med 239:365\u2013369","journal-title":"J Intern Med"},{"key":"1269_CR207","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF03348804","volume":"15","author":"A Borelli","year":"1992","unstructured":"Borelli A, Leite MO, Correa PH et al (1992) Bone histomorphometry in Cushing's syndrome. J Endocrinol Investig 15:783\u2013787","journal-title":"J Endocrinol Investig"},{"key":"1269_CR208","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0026-0495(66)90169-7","volume":"15","author":"BL Riggs","year":"1996","unstructured":"Riggs BL, Jowsey J, Kelly PJ (1996) Quantitative microradiographic study of bone remodeling in Cushing's syndrome. Metabolism 15:773\u2013780","journal-title":"Metabolism"},{"key":"1269_CR209","first-page":"191","volume":"171","author":"PJ Meunier","year":"1984","unstructured":"Meunier PJ, Dempster DW, Edouard C, Chapuy MC, Arlot M, Charhon S (1984) Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 171:191\u2013200","journal-title":"Adv Exp Med Biol"},{"key":"1269_CR210","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1530\/eje.0.1380146","volume":"138","author":"A Sartorio","year":"1998","unstructured":"Sartorio A, Conti A, Ferrero S, Giambona S, Re T, Passini E, Ambrosi B (1998) Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing's syndrome and in patients with adrenal incidentaloma. Eur J Endocrinol 138:146\u2013152","journal-title":"Eur J Endocrinol"},{"key":"1269_CR211","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1530\/eje.0.1410126","volume":"141","author":"K Godang","year":"1999","unstructured":"Godang K, Ueland T, Bollerslev J (1999) Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome. Eur J Endocrinol 141:126\u2013131","journal-title":"Eur J Endocrinol"},{"key":"1269_CR212","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa120","author":"S Athimulam","year":"2020","unstructured":"Athimulam S, Delivanis D, Thomas M et al (2020) The impact of mild autonomous cortisol secretion on bone turnover markers. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa120","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR213","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02067","volume":"154","author":"C Kristo","year":"2006","unstructured":"Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 154:109\u2013118","journal-title":"Eur J Endocrinol"},{"key":"1269_CR214","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s001980200115","volume":"13","author":"A Scillitani","year":"2002","unstructured":"Scillitani A, Dicembrino F, Chiodini I et al (2002) Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporos Int 13:829\u2013834","journal-title":"Osteoporos Int"},{"key":"1269_CR215","first-page":"1863","volume":"83","author":"I Chiodini","year":"1998","unstructured":"Chiodini I, Carnevale V, Torlontano M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 83:1863\u20131867","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR216","first-page":"3303","volume":"82","author":"G Osella","year":"1997","unstructured":"Osella G, Terzolo M, Reimondo G et al (1997) Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. J Clin Endocrinol Metab 82:3303\u20133307","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR217","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/EJE-09-0800","volume":"162","author":"V Camozzi","year":"2010","unstructured":"Camozzi V, Sanguin F, Albigier N et al (2010) Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. Eur J Endocrinol 162:85\u201390. https:\/\/doi.org\/10.1530\/EJE-09-0800","journal-title":"Eur J Endocrinol"},{"key":"1269_CR218","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1046\/j.0300-0664.2001.01454.doc.x","volume":"56","author":"C Di Somma","year":"2002","unstructured":"Di Somma C, Pivonello R, Loche S et al (2002) Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf) 56:153\u2013158. https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01454.doc.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR219","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/bonekey.2016.42","volume":"5","author":"ZE Belaya","year":"2016","unstructured":"Belaya ZE, Iljin AV, Melnichenko GA et al (2016) Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome. Bonekey Rep 5:815. https:\/\/doi.org\/10.1038\/bonekey.2016.42","journal-title":"Bonekey Rep"},{"key":"1269_CR220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s001980170143","volume":"12","author":"B Cortet","year":"2001","unstructured":"Cortet B, Cortet C, Blanckaert F et al (2001) Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome. Osteoporos Int 12:117\u2013123","journal-title":"Osteoporos Int"},{"key":"1269_CR221","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2002.01602.x","volume":"57","author":"CM Francucci","year":"2002","unstructured":"Francucci CM, Pantanetti P, Garrapa GG, Massi F, Arnaldi G, Mantero F (2002) Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. Clin Endocrinol (Oxf) 57:587\u2013593","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR222","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.5650071118","volume":"7","author":"PR Ebeling","year":"1992","unstructured":"Ebeling PR, Peterson JM, Riggs BL (1992) Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 7:1243\u20131250","journal-title":"J Bone Miner Res"},{"key":"1269_CR223","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","volume":"58","author":"C Di Somma","year":"2003","unstructured":"Di Somma C, Pivonello R, Loche S et al (2003) Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 58:302\u2013308","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1269_CR224","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/pgmj.72.849.419","volume":"72","author":"A Sartorio","year":"1996","unstructured":"Sartorio A, Conti A, Ferrario S, Passini E, Re T, Ambrosi B (1996) Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing's syndrome. Postgrad Med J 72:419\u2013422","journal-title":"Postgrad Med J"},{"key":"1269_CR225","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00198-013-2268-y","volume":"24","author":"ZE Belaya","year":"2013","unstructured":"Belaya ZE, Rozhinskaya LY, Melnichenko GA et al (2013) Serum extracellular secreted antagonists of the canonical Wnt\/\u03b2-catenin signaling pathway in patients with Cushing's syndrome. Osteoporos Int 24:2191\u20132199. https:\/\/doi.org\/10.1007\/s00198-013-2268-y","journal-title":"Osteoporos Int"},{"key":"1269_CR226","doi-asserted-by":"publisher","first-page":"E1953","DOI":"10.1210\/jc.2012-2218","volume":"97","author":"AH van Lierop","year":"2012","unstructured":"van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE (2012) Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 97:E1953\u2013E1957. https:\/\/doi.org\/10.1210\/jc.2012-2218","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR227","first-page":"2859","volume":"80","author":"AR Hermus","year":"1995","unstructured":"Hermus AR, Smals AG, Swinkels LM et al (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 80:2859\u20132865","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR228","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s00268-007-9394-7","volume":"32","author":"A Kawamata","year":"2008","unstructured":"Kawamata A, Iihara M, Okamoto T, Obara T (2008) Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World J Surg 32:890\u2013896. https:\/\/doi.org\/10.1007\/s00268-007-9394-7","journal-title":"World J Surg"},{"key":"1269_CR229","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1530\/eje.0.1320422","volume":"132","author":"B Ambrosi","year":"1995","unstructured":"Ambrosi B, Peverelli S, Passini E et al (1995) Abnormalities of endocrine function in patients with clinically \"silent\" adrenal masses. Eur J Endocrinol 132:422\u2013428. https:\/\/doi.org\/10.1530\/eje.0.1320422","journal-title":"Eur J Endocrinol"},{"key":"1269_CR230","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1210\/jcem.84.7.5856","volume":"84","author":"M Torlontano","year":"1999","unstructured":"Torlontano M, Chiodini I, Pileri M et al (1999) Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 84:2381\u20132385","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR231","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1210\/jc.2002-020399","volume":"87","author":"I Chiodini","year":"2002","unstructured":"Chiodini I, Tauchmanov\u00e0 L, Torlontano M et al (2002) Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J Clin Endocrinol Metab 87:5491\u20135494","journal-title":"J Clin Endocrinol Metab"},{"key":"1269_CR232","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0585","volume":"178","author":"R Eastell","year":"2018","unstructured":"Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA (2018) Bone turnover markers: are they clinically useful? Eur J Endocrinol 178:R19\u2013R31. https:\/\/doi.org\/10.1530\/EJE-17-0585","journal-title":"Eur J Endocrinol"},{"key":"1269_CR233","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","volume":"28","author":"P Szulc","year":"2017","unstructured":"Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET (2017) Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int 28:2541\u20132556. https:\/\/doi.org\/10.1007\/s00198-017-4082-4","journal-title":"Osteoporos Int"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01269-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01269-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01269-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T09:40:20Z","timestamp":1619343620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01269-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":233,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01269-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"I have no potential conflict of interest concerning this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}